129 related articles for article (PubMed ID: 36208507)
1. Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers.
Hu M; Li Y; Li J; Zhou H; Liu C; Liu Z; Gong Y; Ying B; Xie Y
Eur J Med Chem; 2022 Dec; 244():114775. PubMed ID: 36208507
[TBL] [Abstract][Full Text] [Related]
2. Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies.
O'Brien NA; Huang HKT; McDermott MSJ; Madrid AM; Luo T; Ayala R; Issakhanian S; Gong KW; Lu M; Zhang J; Slamon DJ
Mol Cancer Ther; 2022 May; 21(5):751-761. PubMed ID: 35417017
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models.
Kulukian A; Lee P; Taylor J; Rosler R; de Vries P; Watson D; Forero-Torres A; Peterson S
Mol Cancer Ther; 2020 Apr; 19(4):976-987. PubMed ID: 32241871
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer.
Sirhan Z; Thyagarajan A; Sahu RP
Mil Med Res; 2022 Jul; 9(1):39. PubMed ID: 35820970
[TBL] [Abstract][Full Text] [Related]
6. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
Mueller V; Wardley A; Paplomata E; Hamilton E; Zelnak A; Fehrenbacher L; Jakobsen E; Curtit E; Boyle F; Harder Brix E; Brenner A; Crouzet L; Ferrario C; Muñoz-Mateu M; Arkenau HT; Iqbal N; Aithal S; Block M; Cold S; Cancel M; Hahn O; Poosarla T; Stringer-Reasor E; Colleoni M; Cameron D; Curigliano G; Siadak M; DeBusk K; Ramos J; Feng W; Gelmon K
Eur J Cancer; 2021 Aug; 153():223-233. PubMed ID: 34214937
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis.
Dong L; Lin S; Zhong L; Nian D; Li Y; Wang R; Zhou W; Weng X; Xu X
Clin Breast Cancer; 2022 Jan; 22(1):e21-e29. PubMed ID: 34238670
[TBL] [Abstract][Full Text] [Related]
8. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer.
Shah M; Wedam S; Cheng J; Fiero MH; Xia H; Li F; Fan J; Zhang X; Yu J; Song P; Chen W; Ricks TK; Chen XH; Goldberg KB; Gong Y; Pierce WF; Tang S; Theoret MR; Pazdur R; Amiri-Kordestani L; Beaver JA
Clin Cancer Res; 2021 Mar; 27(5):1220-1226. PubMed ID: 33055172
[TBL] [Abstract][Full Text] [Related]
10. Tucatinib: First Approval.
Lee A
Drugs; 2020 Jul; 80(10):1033-1038. PubMed ID: 32548668
[TBL] [Abstract][Full Text] [Related]
11. Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer.
Cordero A; Ramsey MD; Kanojia D; Fares J; Petrosyan E; Schwartz CW; Burga R; Zhang P; Rashidi A; Castro B; Xiao T; Lee-Chang C; Miska J; Balyasnikova IV; Ahmed AU; Lesniak MS
Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34969858
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.
Metzger Filho O; Leone JP; Li T; Tan-Wasielewski Z; Trippa L; Barry WT; Younger J; Lawler E; Walker L; Freedman RA; Tolaney SM; Krop I; Winer EP; Lin NU
Ann Oncol; 2020 Sep; 31(9):1231-1239. PubMed ID: 32461105
[TBL] [Abstract][Full Text] [Related]
13. [New European Medicines Agency approval: Tucatinib in association with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer previously treated].
Bonnemort J; Bellesoeur A
Bull Cancer; 2021; 108(7-8):673-675. PubMed ID: 34172272
[No Abstract] [Full Text] [Related]
14. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Tesch ME; Gelmon KA
Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
Shi S; Du Y; Huang L; Cui J; Niu J; Xu Y; Zhu Q
Bioorg Chem; 2022 Mar; 120():105605. PubMed ID: 35081479
[TBL] [Abstract][Full Text] [Related]
16. HER2 Tyrosine Kinase Inhibitors in the Sensitization to Cancers Resistant to HER2 Antibodies.
Singla H; Munshi A
Crit Rev Oncog; 2020; 25(3):241-250. PubMed ID: 33463944
[TBL] [Abstract][Full Text] [Related]
17. New anti-HER2 agents for brain metastasis: histology-agnostic weapons?
Tarantino P; Prat A; Curigliano G
Breast Cancer Res Treat; 2021 Feb; 185(3):879-881. PubMed ID: 33128191
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in vivo evaluation of [
Müller M; Shalgunov V; Hvass L; Jørgensen JT; Kramer V; Staudt M; Battisti UM; Kjaer A; Herth MM
Bioorg Med Chem Lett; 2023 Jan; 80():129088. PubMed ID: 36455802
[TBL] [Abstract][Full Text] [Related]
19. Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer.
Ahn D; Walden D; Bekaii-Saab T
Expert Opin Investig Drugs; 2022 May; 31(5):437-441. PubMed ID: 35289234
[TBL] [Abstract][Full Text] [Related]
20. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
